Holding Sangamo for a December catalyst
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I'm on vacation through August 26. I'm trying to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. After the market close on Wednesday, August 8, Nectar Therapeutics (NKTR) reported earnings of $5.33 a...
My August 17 NKTR calls run out of time–selling out of the Volatility Portfolio
The catalysts are out there, as Fox Mulder, might say, but the August 17 call options with a strike of $60 have run out of time. I'm selling today with a 86% loss since I added them on June 6, 2018. Thanks to the huge gains in previous rounds of Nektar options in...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I'm comfortable with the long-term trajectory of the company's new non-addictive opioid and its leading...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...
Stock or options, Nektar needs some understanding and patience now
It hasn't exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike of $90 I bought on February 25, 2018 are now down...Drug stocks get de-risked after Trump’s plan shows no teeth
President Donald Trump speech last week on drug prices, what he billed as “the most sweeping action in history to lower the price of prescription drugs for the American people,” didn’t deliver any of the ghosts and goblins that drug makers feared. Drug stocks by and large climbed on the proposals. Which turns stocks in the drug sector into one of the most interesting places to stash money for the next six months for investors looking for decent upside and above average safety.
